Convincing evidence has supported the clinical utility of the 21-gene RS assay as both a prognostic and predictive tool in ER-positive, HER2-negative early-stage breast cancer, independent of clinical characteristics (25–27). This evidence concerns the gene ESR1 and breast carcinoma.